Language: English

From Controversy to Conversation: Medicinal Marijuana and Dentistry

Speaker(s): Assistant Professor Anna Matthews, RDH, MS , Assistant Professor Sandra Stramoski, RDH, MSDH

Please login or register

In order to view this webinar you need to login into your account. Don't have an account? You can create one for free.

Despite the growing evidence of its usefulness in management of cancer, HIV/AIDS, epilepsy and other neurological disorders, marijuana remains illegal under the U.S. federal law.

It is a Schedule I controlled substance and has no acceptable medical use according to the U.S. Drug Enforcement Administration. However, many states, as well as other countries, have approved its use for medicinal purposes and a growing number of jurisdictions are approving its recreational use. Two cannabinoid-based drugs are already FDA-approved in the U.S. as Schedule II and Schedule III controlled medications and several others are under investigation. Dental professionals should be aware of the changing legal landscape regarding medicinal and recreational marijuana use, its identified therapeutic and adverse effects, and oral health considerations.

Participants will learn:

  • Cannabinoids, their receptors, and routes of administration;
  • FDA-approved and investigational cannabinoid-based drugs;
  • Diseases and conditions manageable with medicinal marijuana as allowed by law;
  • Dental/oral considerations of the medicinal marijuana use;
  • Future directions of research and oral/dental implications.

Target audience: Dentists, dental assistants and hygienists


Language: English

Release date: Wednesday, January 11, 2017
Expiration date: Saturday, January 11, 2020

You are required to complete a short evaluation form and pass a C.E. Quiz in order to receive the ADA CERP or AGD PACE credit.
AGD PACE subject code(s):
016

“From Controversy to Conversation: Medicinal Marijuana and Dentistry” is co-sponsored by Tribune Group GmbH. Tribune Group GmbH is a recognized ADA CERP and AGD PACE provider.